A new series of 2-amino-6-((4-aryldiazenyl)benzyloxy)-4-chloropyrimidine derivatives 4 -13 and 2,6-diamino-5-arylazo-4-chloro-pyrimidine analogs 15 -20 were synthesized from the pyrimidine scaffolds 3 and 14, respectively, via diazotization with various amines. Nucleophilic displacement at the 2,4-diamino-5-arylazo-6-chloro-pyrimidine 16 by different amines afforded the 4-alkylamino analogs 21 -27. All new compounds were evaluated for their in vitro anti-HIV activity in MT-4 cells as non-nucleoside reverse transcriptase inhibitors on the basis of our previous work. Screening results indicated that 10 and 11 were found to be the only compounds in the series inhibiting HIV-1 replication in cell cultures with EC 50 of > 1.23 and > 2.92 µg mL −1 of a CC 50 of 12.30 and 17.52 µg mL −1 , resulting in a selectivity index of 10 and 6, respectively. In addition, preliminary structure-activity relationships and molecular modeling of these new analogs are detailed in this manuscript.
Introduction
Pyrimidines are an important class of organic compounds, some of which show significant biological activity such as antitumor [1 -6] , antimicrobial [7 -10] , and antihypertensive [11] agents, in addition to their cardiovascular [12, 13] and diuretic [14, 15] properties. Furthermore, pyrimidines are compounds with in vitro biological activity against a wide spectrum of unrelated viruses, such as poliovirus [16] herpes [17] and HI [18 -20] . For the latter, two diarylpyrimidines (DAPY), rilpivirine (1) [21] and etravirine (2) [22, 23] , have been classified as non-nucleoside reverse transcriptase inhibitors (Fig. 1) . Bacimethrin (4-amino-5-(hydroxymethyl)-2-methoxypyrimidine), a pyrimidine antibiotic, is active against several staphylococcal bacteria [24] . Gemcitabine (3), a pyrimidine antimetabolite, is an approved drug in the U. S. for pancreatic cancer and also in combination for certain lung cancer patients [25] , while 2,4-diamino-N 4 -6-diarylpyrimidines were identified to block the proliferation of tumor cell lines in vivo, especially duodenum cancer [26] . Recently, Kim et al. [27] have reported some novel pyrimidine derivatives as potent acid pump antagonists (APAs). Jian et al. [28] have reviewed the biological and medicinal significance of pyrimidines extensively.
In continuation of our ongoing work on the synthesis of new anti-HIV agents and our recent antiviral data on new pyrimidine derivatives [29, 30] , we report here the synthesis of new series of pyrimidines having arylazo residues, and the evaluation of their anti-HIV activity together with a SAR and modeling study.
Results and Discussion
2-Amino-4-benzyloxy-6-chloropyrimidine (3) has been selected as a key intermediate for the synthesis of new azo-pyrimidine derivatives, aiming at the evaluation of their anti-HIV activity. Thus, treatment of 3 with various substituted anilines in the presence of NaNO 2 and HCl first at 0 -5 • C, then at ambient temperature for 15 h, afforded, after purification, mainly the azoaryl-pyrimidine analogs 4 -13 (65 -83 %) (Scheme 1).
The structures of 4 -13 were assigned on the basis of their 1 H, 13 C NMR and mass spectra. The 1 H NMR of 4 -13 showed similar patterns for the aromatic and pyrimidine protons and carbon atoms, where 5-H appeared as singlet in the region δ = 6.54 -6.74 ppm. The singlets in the region δ = 5.31 -5.51 ppm were attributed to the methylene group of the benzyl residue. In the 13 C NMR spectra of 4 -13, the resonances at δ = 172.0 -174.3 ppm were assigned to C-4, while the resonances at δ = 159.0 -162.1 ppm were attributed to C-2 of the pyrimidine ring. The signals of C-6 and C-5 appeared at δ = 161.8 -162.8 and 99.3 -101.0 ppm, respectively. The CH 2 signal appeared at δ = 50.4 -51.6 ppm. The other carbon atoms of the aromatic substituents were fully assigned (see Experimental Section). The proton and carbon systems of the aromatic ring are further identified from the DFQ-COSY spectra [31] . Compound 9 was selected for further NMR experiments. The gradient HMBC [32] NMR spectrum of 9 showed two 2 J C,H couplings between the methylene protons of the benzyl group at δ = 5.33 ppm and C-4 of the aromatic ring at δ = 144.4 ppm as well as C-1 of the aromatic residue at δ = 137.4 ppm. Additionally, a 3 J C,H coupling between the same methylene protons at δ = 5.33 ppm and C-4 of the pyrimidine ring at δ = 172.4 ppm was observed (Fig. 2) . Our work was modified by selecting 14 as a precursor for the synthesis of new 5-arylazopyrimidine derivatives to examine their antiviral activity in comparison to the azoaryl analogs 4 -13. Thus, diazotization of 14, following the same method as described above, by using various substituted anilines gave the desired azoaryl analogs 15 -20 (Scheme 2). The structures of 4 -13 were determined from their 1 H, 13 C NMR and mass spectra, since they showed similar patterns of aromatic and pyrimidine protons (see Experimental Section). In the 13 Next, the derivative 16 was subjected to a nucleophilic displacement of the chlorine atom by treatment with various amines at 90 -100 • C leading to new 4-alkylamino-pyrimidine derivatives 21 -27 (88 -64 %) (Scheme 3). The structures of 21 -27 were established by 1 H, 13 C NMR and mass spectral data. In the 13 C NMR spectra of 21 -27, C-6 and C-4 of the pyrimidine scaffold resonated in the region δ = 163.2 -164.0 ppm, while C-5 and C-6 appeared in the regions δ = 104.7 -110.6 and 152.0 -157.7 ppm, respectively (see Experimental Section). Moreover, all the synthesized compounds were further identified by a 1 H, 13 C HSQC [33] spectroscopic study.
In-vitro anti-HIV activity
Compounds 5 -7 and 12 -17 were tested for their in vitro anti-HIV-1 (strain III B ) and HIV-2 (strain ROD) activity in human T-lymphocyte (MT-4) cells based on an MTT assay [34] . The results are summarized in Table 1 , in which the data for nevirapine (BOE/BIRG587) [35] and azidothymidine (DDN/AZT) [36] were included for comparison. Compounds 10 and 11 were found to be the only compounds in the series inhibiting HIV-1 replication in cell cultures with EC 50 of > 1.23 µg mL −1 and > 2.92 of a CC 50 of 12.30 and 17.52 µg mL −1 , resulting in a selectivity index of 10 and 6, respectively.
From the SAR analysis, we found that the halogen atom on the aromatic ring, e. g. in 10 and 11, were well tolerated in the hydrophobic region of HIV RT and then showed higher activity than those of the derivatives with other substituents of the same series of Scheme 1.
Molecular modeling analysis
Our molecular docking analysis of the new analogs is based on the modeling studies which were performed to understand the binding mode of these analogs with the HIV-RT binding pocket (NNIBP) (PDB code: 3DLG, [37] ). The molecular docking was performed using SYBYL-X 1.1, and the results were visualized with PYMOL [38] .
The prospective ligands were ranked according to the highest binding energy of the best conformers. Thus, the binding energy score for the 4 -13 and 16 -27 series ranged from −6.97 to − 10.02 kcal mol −1 (Table 2) , indicating selectivity and potency profiles of these derivatives to bind the active site of HIV-RT pocket, especially those carrying haloaryl residues (e. g. 10). Compound 10 has been selected to show its binding to the enzyme pocket (Fig. 3) . As shown in Fig. 3 , the aromatic rings of 10 fitted into an arene-rich subpocket surrounded by the aromatic side chains of Tyr179, and Trp227.
Detailed analysis of the binding mode showed that the aromatic rings point toward the aromatic rings of Tyr179 and Trp227 residues apparently developing π-π stacking interactions with the two residues. The pyrimidine backbone is located in the middle of the binding pocket, anchoring the amino substituent at C- 2 in a favorable position for hydrogen bonding with the Lys101 of the reverse transcriptase (RT) enzyme. Overall, the combination of hydrophobic interaction and π-π stacking appears to govern the binding of 10 with HIV RT (binding energy −10.02 kcal mol −1 ). Additionally, synthetic analogs in these hydrophobic domains vary mainly in the size of the C-4 alkyl group (hexyl, pentyl, Bu, Pr and Me) (21 -25). These changes impact most likely the overall hydrophobicity of these inhibitors.
Experimental Section

General
Melting points are uncorrected and were measured on a Büchi melting point apparatus B-545 (Büchi Labortechnik AG, Switzerland). Microanalytical data were obtained with a Vario Elemental Analyzer (Shimadzu, Japan). NMR spectra were recorded on 400 and 600 MHz ( 1 H) and on 150.91 MHz ( 13 C) spectrometers (Bruker, Germany) with TMS as internal standard and on the δ scale in ppm. Sig-nal assignments for protons were performed by selective proton decoupling or by COSY spectra. Heteronuclear assignments were verified by HSQC, HMBC and DFQ-COSY experiments. Mass spectra (EI, 70 eV, and FAB) were recorded on MAT 8200 spectrometers (Finnegan MAT, USA). TLC plates 60 F254 were purchased from Merck.
General procedure for the preparation of 2-amino-6-((4-aryldiazenyl)benzyloxy)-4-chloropyrimidine derivatives 4 -13
A solution of substituted anilines (0.84 mmol) in 6 N HCl (4.0 mL) was cooled to 0 -5 • C, and then NaNO 2 (58 mg, 0.84 mmol) in water (2.0 mL) was added dropwise with stirring. After the addition was completed, the solution was stirred for another 15 min and checked by iodine-starch paper. Urea (50 mg) was added to destroy the excess of HNO 2 . The diazonium salt solution was then poured onto a solution of 2-amino-4-(benzyloxy)-6-chloropyrimidine (3) (180 mg, 0.76 mmol) in water and stirred for 30 min. Potassium acetate (485 mg) was then added, and the mixture was stirred for 16 h at room temperature. The resulting precipitate was filtered, washed with water and dried in a vacuum desiccator over P 2 O 5 to give the desired azo-pyrimidine derivatives.
2-Amino-4-chloro-6-((4-phenyldiazenyl)benzyloxy)pyrimidine (4)
From aniline (78 mg 
2-Amino-6-chloro-4-(4-(ptolyldiazenyl)benzyloxy)pyrimidine (5)
From
4-Amino-6-chloro-4-(4-(4-chlorophenyldiazenyl)benzyloxy)pyrimidine (6)
From 4
2-Amino-4-(4-(4-bromophenyldiazenyl)benzyloxy)-6-chloropyrimidine (7)
From 4-bromoaniline (145 mg 
2-Amino-6-chloro-4-(4-(4-nitrophenyldiazenyl)benzyloxy)pyrimidine (8)
4-((4-((2-Amino-6-chloropyrimidin-4-yloxy)methyl)phenyl)diazenyl)phenyl methanol (9)
2-Amino-4-chloro-6-(4-((4-chloro-3-iodophenyl)diazenyl)benzyloxy)pyrimidine (11)
Methyl 4-((4-((2-amino-4-chloropyrimidin-4-yloxy)methyl)phenyl)diazenyl)benzoate (12)
From methyl 4- 
General procedure for the preparation of 2,6-diamino-5-arylazo-4-chloro-pyrimidine derivatives 15 -20
A solution of a substituted aniline (2.0 mmol) in 6 N HCl (6 mL) was cooled to 0 -5 • C, and then NaNO 2 (138 mg, 2.0 mmol) in water (4 mL) was added dropwise with stirring. After the addition was completed, the solution was stirred for another 15 min and checked by iodine-starch paper to give a blue color. Urea (50 mg) was added to destroy the excess of HNO 2 . The diazonium salt solution was then poured into a solution of 4-amino-6-chloro-1-methylpyrimidin-2-one (14) (260 mg, 1.80 mmol) in water (7 mL) and stirred for 30 min. Potassium acetate (700 mg, 7.14 mmol) was then added, and the mixture was stirred for 16 h at room temperature. The resulting precipitate was collected, washed with water and dried in a vacuum over P 4 O 10 to give the desired product.
2,6-Diamino-4-chloro-5-(pchlorophenylazo)pyrimidine (15)
From 4-chloroaniline (255 mg). Yield: 407 mg (80 %); m. p. 266 -268 • C (lit. [39] : 268 • C). All the physical data are similar to the sample prepared previously. 
2,6-Diamino-4-chloro-5-(pbromophenylazo)pyrimidine (16)
2,6-Diamino-4-chloro-5-(pacetamidophenylazo)pyrimidine (19)
General procedure for the preparation of 2,6-diamino-4-alkylamino-5-(p-bromophenylazo)pyrimidine derivatives 21 -27
A solution of 16 (164 mg, 0.50 mmol) in DMF (20 mL) and an appropriate amine (1.00 mmol) was heated in an oil bath at 90 -100 • C for 4 -5 h. Then water (25 mL) was added, the solution was cooled, and the yellow precipitate was collected, washed with water, and dried. Recrystallization from EtOH afforded the desired product.
